Accordingly, increased serum markers of intestinal barrier damage and epithelial apoptosis, such as intestinal fatty acid-binding protein (I-FABP), and cytokeratin 18 have been found in patients with T1D [59]
Liraglutide is approved as Victoza for T2D and reducing the risk of serious heart problems in individuals with T2D, and Saxenda for weight management
Crucially, it diminishes significantly with subsequent doses the first dose carries the highest risk
Lancet 360 , 901907 (2002)
Proper dosing, consistent administration, and adequate duration all determine success
There is a bipartisan legislative effort in the Senate that could help address this one component of federal oversight